Table 7. Intermediate health outcomes (1)

| Study, year | Study group | Followup | BSA  mean(SD) | PGA\*  n/N | Patient’s Assessment of Global Improvement mean(SD) | Symptom improvement |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  | Pruritus | Pain | Other |
| CT5, 2012 | Etanercept | 2w  4w  8w  12w  18w  24w | -2.64(6.69)†  -7.36(10.89)†  -12.67(13.17)†  -15.43(14.90)†  -16.57(14.70)†  -17.52(14.91)† | 0/21  4/21  6/21  9/21  7/21  11/21 | -0.90(1.58)‡  -1.86(1.28)‡  -2.29(1.79)‡  -2.67(1.56)‡  -2.57(1.99)‡  -1.81(2.20)‡ | -0.67(1.59)§  -1.52(1.33)§  -1.86(2.06)§  -2.10(2.07)§  -1.81(2.06)§  -1.19(2.23)§ | 0.00(0.71)||  0.29(1.19)||  0.19(0.81)||  0.00(0.63)||  -0.05(0.67)||  0.29(1.06)|| |  |
|  | Acitretin | 2w  4w  8w  12w  18w  24w | -0.36(5.54)†  -0.75(7.66)†  -5.14(16.96)†  -5.08(11.89)†  -9.25(16.72)†  -10.30(18.86)† | 1/18  2/18  1/18  1/18  3/18  8/18 | -0.72(1.02)‡  -0.83(1.04)‡  -1.67(1.71)‡  -1.61(1.72)‡  -1.83(1.76)‡  -1.72(1.93)‡ | -0.39(1.29)§  -0.39(2.03)§  -1.28(1.71)§  -1.22(1.73)§  -1.17(1.62)§  -1.06(1.89)§ | -0.44(1.10)||  -0.72(1.81)||  -0.56(1.72)||  -0.44(2.36)||  -0.44(1.85)||  -0.61(2.03)|| |  |
| Gelfand, 2012 | MTX | --- | 3.0(1.0 to 6.0)¶ | 1.7(1.3 to 2.0)¶ | --- | --- | --- | --- |
|  | Adalimumab | --- | 2.0(0.7 to 5.0)¶ | 1.3(1.0 to 1.7)¶ | --- | --- | --- | --- |
|  | Etanercept | --- | 2.0(0.5 to 4.5)¶ | 1.7(1.0 to 2.0)¶ | --- | --- | --- | --- |
|  | Ustekinumab | --- | 3.0(0.6 to 9.1)¶ | 1.7(1.0 to 2.1)¶ | --- | --- | --- | --- |
|  | NB-UVB | --- | 3.3(1.0 to 6.5)¶ | 1.7(1.0 to 2.0)¶ | --- | --- | --- | --- |
| Barker, 2011 | Infliximab | 16w  26w\*\* | ---  --- | 496/653  477/653 | ---  --- | ---  --- | ---  --- | ---  --- |
|  | MTX | 16w  26w\*\* | ---  --- | 82/215  60/215 | ---  --- | ---  --- | ---  --- | ---  --- |
|  | Infliximab transitioned to MTX | 18w  22w  26w | ---  ---  --- | 0/9  1/9  2/9 | ---  ---  --- | ---  ---  --- | ---  ---  --- | ---  ---  --- |
|  | MTX transitioned to infliximab | 18w  22w  26w | ---  ---  --- | 19/63  45/63  47/63 | ---  ---  --- | ---  ---  --- | ---  ---  --- | ---  ---  --- |
| Inzinger, 2011 | Adalimumab | --- | --- | --- | --- | --- | --- | --- |
|  | Alefacept | --- | --- | --- | --- | --- | --- | --- |
|  | Etanercept | --- | --- | --- | --- | --- | --- | --- |
|  | Infliximab | --- | --- | --- | --- | --- | --- | --- |
|  | Ustekinumab | --- | --- | --- | --- | --- | --- | --- |
|  | PUVA | --- | --- | --- | --- | --- | --- | --- |
| Strober, 2011 | MTX transitioned to adalimumab | 0w  2w  4w  8w  16w | ---  ---  ---  ---  --- | 1/41  0/41  13/41  22/41  25/41  61% (95%CI 45 to 76)†† | ---  ---  ---  ---  --- | ---  ---  ---  ---  -2.9(3.9)‡‡ | ---  ---  ---  ---  -14.7(24.4)§§ | ---  ---  ---  --- |
|  | NB-UVB transitioned to adalimumab | 0w  2w  4w  8w  16w | ---  ---  ---  ---  --- | 0/29  3/29  6/29  13/29  14/29  48% (95%CI 29 to 67)†† | ---  ---  ---  ---  --- | ---  ---  ---  ---  -3.0(2.96)‡‡ | ---  ---  ---  ---  -21.4(30.0)§§ | ---  ---  ---  --- |
| Garavaglia, 2010 | CyA transitioned to etanercept | --- | --- | --- | --- | --- | --- | --- |
| Caproni, 2009 | Etanercept | --- | --- | --- | --- | --- | --- | --- |
|  | Acitretin | --- | --- | --- | --- | --- | --- | --- |
| Mazzotta, 2009 | Nonbiologics or phototherapy transitioned to etanercept|||| | --- | --- | --- | --- | --- | --- | --- |
| Gisondi, 2008a | Etanercept | 24w | -80.0%¶¶ | --- | --- | --- | --- | --- |
|  | Acitretin | 24w | -45.8%¶¶ | --- | --- | --- | --- | --- |
| Gisondi, 2008b | Etanercept | --- | --- | --- | --- | --- | --- | --- |
|  | Infliximab | --- | --- | --- | --- | --- | --- | --- |
|  | MTX | --- | --- | --- | --- | --- | --- | --- |
| Saurat, 2008 | Adalimumab | 4w  8w  12w  16w | ---  ---  ---  --- | 17/108  52/108  72/108  79/108 | ---  ---  ---  -1.6(NR)§ | ---  ---  ---  -5.0(NR) | ---  ---  ---  -24.2(NR) | ---  ---  ---  --- |
|  | MTX | 4w  8w  12w  16w | ---  ---  ---  --- | 4/110  10/110  24/110  33/110 | ---  ---  ---  -1.2(NR)§ | ---  ---  ---  -3.5(NR) | ---  ---  ---  -11.1(NR) | ---  ---  ---  --- |
|  | MTX transitioned to adalimumab | --- | --- | --- | --- | --- | --- | --- |
| Magliocco, 2007 | CyA transitioned to alefacept | 13w  25w  37w  48w | ---  ---  ---  --- | ---  4.75(NR)\*\*\*  4.33(NR)\*\*\*  4.33(NR)\*\*\* | ---  ---  ---  --- | ---  ---  ---  --- | ---  ---  ---  --- | ---  ---  ---  --- |
| Costanzo, 2005 | Nonbiologics transitioned to etanercept††† | --- | --- | --- | --- | --- | --- | --- |

Abbreviations: BSA=body surface area; CI=confidence interval; CyA=cyclosporine; MTX=methotrexate; n/N=number of patients per total population; NB-UVB=narrowband ultraviolet B; NR=not reported; PASI=Psoriasis Area and Severity Index; PGA=Physician’s Global Assessment; PUVA=psoralen plus ultraviolet A; SD=standard deviation; VAS=visual analog scale; w=week(s); ---=not reported

\* Number of patients achieving a PGA score of “clear” or “minimal”, unless otherwise noted

† Mean(SD) change from baseline

‡ Mean(SD) change from baseline in SGA of psoriasis

§ Mean(SD) change from baseline in SGA of itching

|| Mean(SD) change from baseline is SGA of joint pain

¶ Median (IQR)

\*\* Includes patients who switched treatments at week 16 as nonresponders

†† 95%CI reported as percentage of respective population

‡‡ Mean(SD) change from baseline in Psoriasis-related Pruritus Assessment

§§ Mean(SD) change from baseline in VAS for pain involving psoriatic plaques and/or psoriatic arthritis

|||| CyA, corticosteroids, fumaric acid esters, MTX, retinoids, PUVA

¶¶ Mean percentage change from baseline

\*\*\* Mean(SD) PGA

††† CyA, corticosteroids, MTX, retinoids